1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Mental Health Analysis & Statistics in the United Kingdom, July 2020

Mental Health Analysis & Statistics in the United Kingdom, July 2020

1-30 of about 100 reports

Diabetic Peripheral Neuropathy (DPN) - Epidemiology Forecast-2030

  • $ 3750
  • Jul 2020
  • 80 pages

‘Diabetic Peripheral Neuropathy (DPN) - Epidemiology Forecast-2030’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology trends of Diabetic Peripheral Neuropathy ...

  • Mental Health
  • Neurological Disorder
  • Pathology
  • United Kingdom
  • United States

Treatment-resistant depression (TRD) - Epidemiology Forecast - 2030

  • $ 3750
  • June 2020
  • 100 pages

‘Treatment-resistant depression (TRD)– Epidemiology Forecast—2030’ report delivers an in-depth understanding of the Treatment-resistant depression, historical and forecasted epidemiology in the ...

  • Depression
  • Mental Health
  • Pathology
  • Therapy
  • United Kingdom

Pompe Disease - Epidemiology Forecast to 2030

  • $ 3750
  • May 2020
  • 100 pages

‘Pompe Disease (PD) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Pompe Disease in the United States, EU5 (Germany, ...

  • Mental Health
  • Neurological Disorder
  • Pathology
  • France
  • United Kingdom

Frontotemporal Dementia (FTD)- Epidemiology Forecast to 2030

  • $ 3750
  • May 2020
  • 100 pages

‘Frontotemporal Dementia (FTD) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Frontotemporal Dementia in the United ...

  • Mental Health
  • Neurological Disorder
  • Pathology
  • United Kingdom
  • United States

Postpartum Depression - Epidemiology Forecast to 2030

  • $ 3750
  • April 2020
  • 100 pages

‘Postpartum Depression (PPD) - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted Postpartum Depression (PPD) epidemiology in the United ...

  • Depression
  • Mental Health
  • Germany
  • United Kingdom
  • Forecast

Duchenne Muscular Dystrophy - Epidemiology Forecast to 2030

  • $ 3750
  • April 2020
  • 100 pages

‘Duchenne Muscular Dystrophy (DMD) - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted Duchenne Muscular Dystrophy (DMD) epidemiology ...

  • Mental Health
  • Neurological Disorder
  • Pathology
  • United Kingdom
  • United States

Adrenoleukodystrophy (ALD) - Epidemiology Forecast to 2030

  • $ 3750
  • April 2020
  • 83 pages

Overview ‘Adrenoleukodystrophy (ALD) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Adrenoleukodystrophy epidemiology in the 7MM, ...

  • Mental Health
  • Neurological Disorder
  • Japan
  • United Kingdom
  • United States

United Kingdom Neurology Devices Market Outlook to 2025 - Hydrocephalus shunts, Interventional Neuroradiology, Minimally Invasive Neurosurgery and Others.

  • $ 5995
  • January 2020
  • 249 pages

United Kingdom Neurology Devices Market Outlook to 2025 - Hydrocephalus shunts, Interventional Neuroradiology, Minimally Invasive Neurosurgery and Others. Summary new report, United Kingdom Neurology ...

  • Catheter
  • Hospital
  • Mental Health
  • United Kingdom
  • Medtronic, Inc.

Beta Secretase 1 - Pipeline Review, H1 2020

  • $ 3500
  • January 2020
  • 34 pages

Beta Secretase 1 - Pipeline Review, H1 2020 Summary According to the recently published report ’Beta Secretase 1 - Pipeline Review, H1 2020’; Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid ...

  • Dementia
  • Mental Health
  • Therapy
  • United Kingdom
  • Product Initiative

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2020

  • $ 2000
  • January 2020
  • 87 pages

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2020 Summary The latest Pharmaceutical and Healthcare disease pipeline guide Cognitive Impairment Associated With Schizophrenia ...

  • Mental Health
  • Psychotic Disorder
  • Therapy
  • United Kingdom
  • Product Initiative

Collagen Solutions Plc (COS) - Product Pipeline Analysis, 2019 Update

  • $ 750
  • December 2019
  • 36 pages

Summary Collagen Solutions Plc (Collagen Solutions), formerly Healthcare Investment Opportunities Plc, is a medical device company that develops, manufactures and supplies medical grade collagen biomaterials ...

  • Mental Health
  • United Kingdom
  • Company
  • Supply
  • Collagen Solutions plc

Learning Disability, Mental Health & Substance Abuse Facilities in the UK - Industry Market Research Report

  • $ 985
  • December 2019
  • 33 pages

Ups and downs: Revenue has fluctuated, but has fallen overall during the past five years Abstract Learning Disability, Mental Health & Substance Abuse Facilities in the UK Operators in this industry ...

  • Mental Health
  • Neurological Disorder
  • Pathology
  • United Kingdom
  • Forecast

Embolotherapy Market

  • $ 4900
  • September 2019
  • 336 pages

Embolotherapy Market Research Report: By Product (Embolic Agents, Support Devices), Procedure (Transcatheter Arterial Embolization, Transarterial Radioembolization/Selective Internal Radiation Therapy, ...

  • Mental Health
  • Pathology
  • France
  • United Kingdom
  • Demand

Latuda

  • $ 10000
  • March 2019
  • 39 pages

Latuda (lurasidone; Sumitomo Dainippon/Angelini) contains the atypical antipsychotic lurasidone, which acts as an antagonist of dopamine receptors D2, and serotonin receptors 5-HT2A. By inhibiting the ...

  • Mental Health
  • Pathology
  • Psychotic Disorder
  • Japan
  • United Kingdom

Alzheimer’s Disease KOL Interview – UK

  • $ 599
  • January 2019
  • 14 pages

Overview This interview with a UK key opinion leader (KOL) provides an overview of cost-effectiveness criteria that may be required to bring Alzheimer’s disease products successfully to the clinic in ...

  • Dementia
  • Mental Health
  • Pathology
  • United Kingdom

Major Depressive Disorder KOL Interview – UK

  • $ 599
  • December 2018
  • 11 pages

Overview A UK key opinion leader (KOL) provides insight into the critical unmet needs in the depression market, along with future trends. Key late-phase pipeline drugs for major depressive disorder and ...

  • Depression
  • Mental Health
  • United Kingdom
  • Forecast
  • Market Size

University of Edinburgh - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • December 2018
  • 43 pages

Summary University of Edinburgh (UE) is an educational service provider that offers undergraduate and postgraduate programs.The university offers courses in the areas of accounting, art, business, chemistry, ...

  • Dementia
  • Healthcare
  • Mental Health
  • Pharmaceutical
  • United Kingdom

University of Liverpool - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • December 2018
  • 55 pages

Summary University of Liverpool is an academic and research university that provides undergraduate, postgraduate, and online programs.The university owns scientific teaching laboratories. It offers services ...

  • Healthcare
  • Mental Health
  • Therapy
  • United Kingdom
  • Eisai Co., Ltd.

Cytox Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • November 2018
  • 18 pages

Summary Cytox Ltd (Cytox) is a prognostic and diagnostic service provider that develops neurodegenerative disorders services.The company offers development of tests to identify individuals at risk of cognitive ...

  • Mental Health
  • Pharmaceutical
  • United Kingdom
  • Deals & Alliance
  • Cytox Limited

Heptares Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • November 2018
  • 41 pages

Summary Heptares Therapeutics Ltd (Heptares) a subsidiary of Sosei Group Corp is a drug discovery company that develops small-molecule drugs.The company develops drugs for targeting G-protein-coupled receptors ...

  • Mental Health
  • Pharmaceutical
  • Therapy
  • United Kingdom
  • Heptares Therapeutics Limited

Cytox Ltd - Medical Equipment - Deals and Alliances Profile

  • $ 250
  • November 2018
  • 21 pages

Summary Cytox Ltd (Cytox) is a prognostic and diagnostic service provider that develops neurodegenerative disorders services.The company offers development of tests to identify individuals at risk of cognitive ...

  • Medical Device
  • Mental Health
  • United Kingdom
  • Deals & Alliance
  • Cytox Limited

Mission Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • November 2018
  • 25 pages

Summary Mission Therapeutics Ltd (Mission) is a provider of deubiquitylating enzyme drug discovery and development programs. The company develops USP30, USP10 and UHCL1 for patients with mitochondria diseases, ...

  • Healthcare
  • Mental Health
  • Therapy
  • United Kingdom
  • Company

University of Sheffield - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • November 2018
  • 33 pages

Summary University of Sheffield (Sheffield University) is an educational service provider that offers undergraduate, postgraduate, research and certificate programmes.The university offers courses in various ...

  • Healthcare
  • Mental Health
  • Pharmaceutical
  • Therapy
  • United Kingdom

Cantabio Pharmaceuticals Inc (CTBO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • October 2018
  • 25 pages

Summary Cantabio Pharmaceuticals Inc (Cantabio Pharmaceuticals) is a biotechnology company that concentrates on the commercializing of novel therapies for Parkinson’s disease, Alzheimer’s disease and ...

  • Mental Health
  • Pharmaceutical
  • United Kingdom
  • Corporate Finance
  • Cantabio Pharmaceuticals, Inc.

IXICO Plc (IXI) - Medical Equipment - Deals and Alliances Profile

  • $ 250
  • October 2018
  • 29 pages

Summary IXICO Plc (IXICO), formerly Phytopharm plc is a provider of clinical trial services and technology for the evaluation of imaging endpoints and assessing the safety and efficacy of drugs.The company ...

  • Medical Device
  • Medical Equipment
  • Mental Health
  • United Kingdom
  • IXICO plc

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H2 2018

  • $ 3500
  • October 2018
  • 56 pages

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H2 2018 Summary Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein ...

  • Mental Health
  • Therapy
  • United Kingdom
  • Product Initiative
  • AMO Pharma

Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Pipeline Review, H2 2018

  • $ 3500
  • October 2018
  • 92 pages

Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Pipeline ...

  • Cancer
  • Mental Health
  • United Kingdom
  • Product Initiative
  • Oryzon Genomics S.A.

IXICO Plc (IXI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • October 2018
  • 32 pages

Summary IXICO Plc (IXICO), formerly Phytopharm plc is a provider of clinical trial services and technology for the evaluation of imaging endpoints and assessing the safety and efficacy of drugs.The company ...

  • Mental Health
  • United Kingdom
  • Company
  • Company Financials
  • IXICO plc

SomaLogic Inc - Product Pipeline Analysis, 2018 Update

  • $ 750
  • August 2018
  • 48 pages

Summary SomaLogic Inc (SomaLogic) is a life science company that discovers, develops and commercializes life science research tools and clinical diagnostic products.The company’s products include SOMAscan ...

  • Diagnostics
  • Mental Health
  • Pathology
  • United Kingdom
  • SomaLogic, Inc.

Amyotrophic Lateral Sclerosis: Epidemiology Forecast to 2027

  • $ 3995
  • July 2018
  • 32 pages

Amyotrophic Lateral Sclerosis: Epidemiology Forecast to 2027 Summary Amyotrophic Lateral Sclerosis (ALS) is often referred to as "Lou Gehrig’s Disease" after the famous baseball player who was diagnosed ...

  • Dementia
  • Mental Health
  • United Kingdom
  • United States
  • Forecast
About 1700 reports

Download Unlimited Documents from Trusted Public Sources

View report >

Neurological Disorder Statistics in the UK

  • April 2020
  • 48 pages
  • Caring Services
  • Mental Health
  • Neurological Disorder
  • Social Care
  • United Kingdom

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on